Advertisement

The Epidemiology of Diabetic Retinopathy

  • Ronald Klein
Part of the Contemporary Diabetes book series (CDI)

Abstract

Over the past 25 years, there have been dramatic changes in the management of diabetes and its complications resulting from the application of evidence from randomized controlled clinical trials showing the efficacy of photocoagulation treatment (e.g., Diabetic Retinopathy Study [DRS], Early Treatment Diabetic Retinopathy Study [ETDRS]), and glycemic and blood pressure control (e.g., Diabetes Control and Complications Trial [DCCT], United Kingdom Prospective Diabetes Study [UKPDS]) (1, 2, 3, 4, 5, 6). Translation of these findings to clinical care have resulted in changes in the incidence and progression of retinopathy and resultant visual loss in persons with diabetes. The purpose of this chapter is to review the epidemiology of diabetic retinopathy over this period of change.

Key Words

Diabetic retinopathy epidemiology incidence risk factors 

Notes

Acknowledgments

This chapter was supported by National Institutes of Health grant # EY016379 (R Klein and BEK Klein).

References

  1. 1.
    The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583–600.Google Scholar
  2. 2.
    Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology. 1991;98:757–65.Google Scholar
  3. 3.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.Google Scholar
  4. 4.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.Google Scholar
  5. 5.
    UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovas-cular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.Google Scholar
  6. 6.
    Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normoten-sive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–97.PubMedGoogle Scholar
  7. 7.
    Hirschberg J. Ueber Diabetische Netzhautentzundung. Deutsche Medicinische Wochenschrift. 1893;16:1181–5, 1236–9.Google Scholar
  8. 8.
    Friedenwald H. The Doyne memorial lecture: pathological changes in the retinal blood-vessels in arterio-sclerosis and hypertension. Trans Ophthal Soc UK. 1930;50:531.Google Scholar
  9. 9.
    University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes. 1982;31 Suppl 5:1–81.Google Scholar
  10. 10.
    Vision problems in the U.S. Data analysis. Definitions, data sources, detailed data tables, analysis, interpetation. In: New York: National Society to Prevent Blindness; 1980:1–46.Google Scholar
  11. 11.
    West KM. Epidemiology of diabetes and its vascular lesions. New York: Elsevier; 1978.Google Scholar
  12. 12.
    Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol. 1984;119:54–61.PubMedGoogle Scholar
  13. 13.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520–6.PubMedGoogle Scholar
  14. 14.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527–32.PubMedGoogle Scholar
  15. 15.
    Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98:786–806.Google Scholar
  16. 16.
    Klein BE, Davis MD, Segal P, et al. Diabetic retinopathy. Assessment of severity and progression. Ophthalmology. 1984;91:10–7.PubMedGoogle Scholar
  17. 17.
    Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98:823–33.Google Scholar
  18. 18.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. I V. Diabetic macular edema. Ophthalmology. 1984;91:1464–74.PubMedGoogle Scholar
  19. 19.
    Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143–56.PubMedGoogle Scholar
  20. 20.
    Lopez IM, Diez A, Velilla S, Rueda A, Alvarez A, Pastor CJ. Prevalence of diabetic retinopathy and eye care in a rural area of Spain. Ophthalmic Epidemiol. 2002;9:205–14.PubMedGoogle Scholar
  21. 21.
    Broadbent DM, Scott JA, Vora JP, Harding SP. Prevalence of diabetic eye disease in an inner city population: the Liverpool Diabetic Eye Study. Eye. 1999;13 (Pt 2):160–5.PubMedGoogle Scholar
  22. 22.
    West SK, Klein R, Rodriguez J, et al. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care. 2001;24:1204–9.PubMedGoogle Scholar
  23. 23.
    McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project. Br J Ophthalmol. 2000;84:865–70.PubMedGoogle Scholar
  24. 24.
    Toeller M, Buyken AE, Heitkamp G, Berg G, Scherbaum WA, EURODIAB Complications Study Group. Prevalence of chronic complications, metabolic control and nutritional intake in type 1 diabetes: comparison between different European regions. Horm Metab Res. 1999;31:680–5.PubMedGoogle Scholar
  25. 25.
    Leske MC, Wu S Y, Hyman L, et al. Diabetic retinopathy in a black population: the Barbados Eye Study. Ophthalmology. 1999;106:1893–9.PubMedGoogle Scholar
  26. 26.
    Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community: the Blue Mountains Eye Study. Ophthalmology. 1998;105:406–11.PubMedGoogle Scholar
  27. 27.
    Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology. 1992;99:58–62.PubMedGoogle Scholar
  28. 28.
    Kempen JH, O'Colmain BJ, Leske MC, et al.. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–63.PubMedGoogle Scholar
  29. 29.
    Lecaire T, Palta M, Zhang H, Allen C, Klein R, D'Alessio D. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4–14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol. 2006;164:143–50.PubMedGoogle Scholar
  30. 30.
    Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55:1463–9.PubMedGoogle Scholar
  31. 31.
    Dwyer MS, Melton LJ, III, Ballard DJ, Palumbo PJ, Trautmann JC, Chu CP. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care. 1985;8:316–22.PubMedGoogle Scholar
  32. 32.
    Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care. 1988;11:246–51.PubMedGoogle Scholar
  33. 33.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107:237–43.PubMedGoogle Scholar
  34. 34.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107:244–9.PubMedGoogle Scholar
  35. 35.
    Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI. The incidence of macular edema. Ophthalmology. 1989;96:1501–10.PubMedGoogle Scholar
  36. 36.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112:1217–28.PubMedGoogle Scholar
  37. 37.
    Henricsson M, Nystrom L, Blohme G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:349–54.PubMedGoogle Scholar
  38. 38.
    Lloyd CE, Becker D, Ellis D, Orchard TJ. Incidence of complications in insulin-dependent diabetes mellitus: a survival analysis. Am J Epidemiol. 1996;143:431–41.PubMedGoogle Scholar
  39. 39.
    Klein R, Palta M, Allen C, Shen G, Han DP, D'Alessio DJ. Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol. 1997;115:351–6.PubMedGoogle Scholar
  40. 40.
    Tudor SM, Hamman RF, Baron A, Johnson DW, Shetterly SM. Incidence and progression of diabetic retinopathy in Hispanics and non-Hispanic whites with type 2 diabetes: San Luis Valley Diabetes Study, Colorado. Diabetes Care. 1998;21:53–61.PubMedGoogle Scholar
  41. 41.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–15.PubMedGoogle Scholar
  42. 42.
    Porta M, Sjoelie AK, Chaturvedi N, et al. Risk factors for progression to proliferative diabetic retin-opathy in the EURODIAB Prospective Complications Study. Diabetologia. 2001;44:2203–9.PubMedGoogle Scholar
  43. 43.
    Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye. 2002;16:140–5.PubMedGoogle Scholar
  44. 44.
    Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195–200.PubMedGoogle Scholar
  45. 45.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X V. The long-term incidence of macular edema. Ophthalmology. 1995;102:7–16.PubMedGoogle Scholar
  46. 46.
    Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26:1258–64.PubMedGoogle Scholar
  47. 47.
    Rabb MF, Gagliano DA, Sweeney HE. Diabetic retinopathy in blacks. Diabetes Care. 1990;13:1202–6.PubMedGoogle Scholar
  48. 48.
    Varma R, Torres M, Pena F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111:1298–306.PubMedGoogle Scholar
  49. 49.
    Roy MS. Diabetic retinopathy in African Americans with type 1 diabetes: The New Jersey 725: I. Methodology, population, frequency of retinopathy, and visual impairment. Arch Ophthalmol. 2000;118:97–104.PubMedGoogle Scholar
  50. 50.
    Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopa-thy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004;122:546–51.PubMedGoogle Scholar
  51. 51.
    Roy MS, Klein R. Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725. Arch Ophthalmol. 2001;119:251–9.PubMedGoogle Scholar
  52. 52.
    Roy MS, Affouf M. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol. 2006;124:1297–306.PubMedGoogle Scholar
  53. 53.
    Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology. 2002;109:1225–34.PubMedGoogle Scholar
  54. 54.
    Klein R, Marino EK, Kuller LH, et al. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. Br J Ophthalmol. 2002;86:84–90.PubMedGoogle Scholar
  55. 55.
    Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care. 1998;21:1230–5.PubMedGoogle Scholar
  56. 56.
    Wong T Y, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446–55.PubMedGoogle Scholar
  57. 57.
    Berinstein DM, Stahn RM, Welty TK, Leonardson GR, Herlihy JJ. The prevalence of diabetic retin-opathy and associated risk factors among Sioux Indians. Diabetes Care. 1997;20:757–9.PubMedGoogle Scholar
  58. 58.
    Lee ET, Lu M, Bennett PH, Keen H. Vascular disease in younger-onset diabetes: comparison of European, Asian and American Indian cohorts of the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S78–81.PubMedGoogle Scholar
  59. 59.
    Looker HC, Krakoff J, Knowler WC, Bennett PH, Klein R, Hanson RL. Longitudinal studies of incidence and progression of diabetic retinopathy assessed by retinal photography in Pima Indians. Diabetes Care. 2003;26:320–6.PubMedGoogle Scholar
  60. 60.
    McNeely MJ, Boyko EJ. Diabetes-related comorbidities in Asian Americans: results of a national health survey. J Diabetes Complications. 2005;19:101–6.PubMedGoogle Scholar
  61. 61.
    Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care. 2003;26:1224–9.PubMedGoogle Scholar
  62. 62.
    Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care. 1990;13:1034–8.PubMedGoogle Scholar
  63. 63.
    Hanis CL, Hallman D. Genetics of diabetic retinopathy. Curr Diab Rep. 2006;6:155–61.PubMedGoogle Scholar
  64. 64.
    Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2006;114:275–94.PubMedGoogle Scholar
  65. 65.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154:2169–78.PubMedGoogle Scholar
  66. 66.
    Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–61.Google Scholar
  67. 67.
    Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. Prospective Diabetes Study 61. Diabetes Care. 2002;25:1410–7.PubMedGoogle Scholar
  68. 68.
    Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124:90–6.PubMedGoogle Scholar
  69. 69.
    Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–98.Google Scholar
  70. 70.
    The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA. 1988;260:37–41.Google Scholar
  71. 71.
    Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet. 1983;1:200–4.PubMedGoogle Scholar
  72. 72.
    Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes. 1985;34 Suppl 3:74–9.PubMedGoogle Scholar
  73. 73.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed). 1986;293:1195–9.Google Scholar
  74. 74.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mel-litus: the Oslo study. Br Med J (Clin Res Ed). 1985;290:811–5.Google Scholar
  75. 75.
    The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–15.Google Scholar
  76. 76.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–9.Google Scholar
  77. 77.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.Google Scholar
  78. 78.
    Gray A, Raikou M, McGuire A, et al., United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320:1373–8.PubMedGoogle Scholar
  79. 79.
    Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care. 2001;24:942–5.PubMedGoogle Scholar
  80. 80.
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1994;17:616–23.Google Scholar
  81. 81.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care. 1996;19:744–50.PubMedGoogle Scholar
  82. 82.
    Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care. 2000;23:754–8.PubMedGoogle Scholar
  83. 83.
    Wagener HP, Dry TJ, Wilder RM. Retinitis in diabetes. N Engl J Med. 1934;211:1131–7.Google Scholar
  84. 84.
    Kohner EM. Diabetic retinopathy. Br Med Bull. 1989;45:148–73.PubMedGoogle Scholar
  85. 85.
    Patel V, Rassam SM, Chen HC, Jones M, Kohner EM. Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Metabolism. 1998;47:28–33.PubMedGoogle Scholar
  86. 86.
    Dorf A, Ballintine EJ, Bennett PH, Miller M. Retinopathy in Pima Indians. Relationships to glucose level, duration of diabetes, age at diagnosis of diabetes, and age at examination in a population with a high prevalence of diabetes mellitus. Diabetes. 1976;25:554–60.PubMedGoogle Scholar
  87. 87.
    West KM, Erdreich LJ, Stober JA. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes. 1980;29:501–8.PubMedGoogle Scholar
  88. 88.
    Ballard DJ, Melton LJ, III, Dwyer MS, et al. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care. 1986;9:334–42.PubMedGoogle Scholar
  89. 89.
    Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of diabetic complications in relation to risk factors. Diabetes. 1986;35:1332–9.PubMedGoogle Scholar
  90. 90.
    Sjolie AK. Ocular complications in insulin treated diabetes mellitus. An epidemiological study. Acta Ophthalmol Suppl. 1985;172:1–77.PubMedGoogle Scholar
  91. 91.
    Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes. 1988;37:878–84.PubMedGoogle Scholar
  92. 92.
    Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM: San Luis Valley Diabetes Study. Diabetes. 1989;38:1231–7.PubMedGoogle Scholar
  93. 93.
    McLeod BK, Thompson JR, Rosenthal AR. The prevalence of retinopathy in the insulin-requiring diabetic patients of an English country town. Eye. 1988;2 (Pt 4):424–30.PubMedGoogle Scholar
  94. 94.
    Kostraba JN, Klein R, Dorman JS, et al. The Epidemiology of Diabetes Complications Study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol. 1991;133:381–91.PubMedGoogle Scholar
  95. 95.
    Lee ET, Lee VS, Lu M, Russell D. Development of proliferative retinopathy in NIDDM. A follow-up study of American Indians in Oklahoma. Diabetes. 1992;41:359–67.PubMedGoogle Scholar
  96. 96.
    Lee ET, Lee VS, Kingsley RM, et al. Diabetic retinopathy in Oklahoma Indians with NIDDM. Incidence and risk factors. Diabetes Care. 1992;15:1620–7.PubMedGoogle Scholar
  97. 97.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med. 1989;149:2427–32.PubMedGoogle Scholar
  98. 98.
    Klein BE, Klein R, Moss SE, Palta M. A cohort study of the relationship of diabetic retinopathy to blood pressure. Arch Ophthalmol. 1995;113:601–6.PubMedGoogle Scholar
  99. 99.
    Klein R, Moss SE, Sinaiko AR, et al. The relation of ambulatory blood pressure and pulse rate to retinopa-thy in type 1 diabetes mellitus: the Renin-Angiotensin System Study. Ophthalmology. 2006;113:2231–6.PubMedGoogle Scholar
  100. 100.
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.PubMedGoogle Scholar
  101. 101.
    Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761–9.PubMedGoogle Scholar
  102. 102.
    Chaturvedi N, Sjolie AK, Stephenson JM, et al., The EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet. 1998;351:28–31.PubMedGoogle Scholar
  103. 103.
    Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopa-thy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122:1631–40.PubMedGoogle Scholar
  104. 104.
    Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic micro-vascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23 Suppl 2:B54–64.PubMedGoogle Scholar
  105. 105.
    Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 Randomised Study. Lancet. 1999;353:617–22.PubMedGoogle Scholar
  106. 106.
    Chaturvedi N, Sjoelie AK, Svensson A. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst. 2002;3:255–61.PubMedGoogle Scholar
  107. 107.
    American Diabetes Association. Clinical Practice Recommendations 2005. Diabetes Care. 2005;28 Suppl 1:S1–79.Google Scholar
  108. 108.
    Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension. 2002;40:464–9.PubMedGoogle Scholar
  109. 109.
    Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–7.PubMedGoogle Scholar
  110. 110.
    Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–42.PubMedGoogle Scholar
  111. 111.
    Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261–5.PubMedGoogle Scholar
  112. 112.
    Chew E Y, Klein ML, Ferris FL, III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114:1079–84.PubMedGoogle Scholar
  113. 113.
    van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn Study. Diabetes Care. 2002;25:1320–5.PubMedGoogle Scholar
  114. 114.
    Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes. 2004;53:2883–92.PubMedGoogle Scholar
  115. 115.
    Santos A, Salguero ML, Gurrola C, Munoz F, Roig-Melo E, Panduro A. The epsilon4 allele of apoli-poprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genet. 2002;23:13–9.PubMedGoogle Scholar
  116. 116.
    Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes. 1968;17:458–67.PubMedGoogle Scholar
  117. 117.
    Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112:385–91.PubMedGoogle Scholar
  118. 118.
    Freyberger H, Schifferdecker E, Schatz H. [Regression of hard exudates in diabetic background retin-opathy in therapy with etofibrate antilipemic agent]. Med Klin (Munich). 1994;89:594–7, 633.Google Scholar
  119. 119.
    Dale J, Farmer J, Jones AF, Gibson JM, Dodson PM. Diabetic ischaemic and exudative maculopathy: are their risk factors different? Diab Med. 2000;17:47.Google Scholar
  120. 120.
    Jerneld B. Prevalence of diabetic retinopathy. A population study from the Swedish island of Gotland. Acta Ophthalmol Suppl. 1988;188:3–32.PubMedGoogle Scholar
  121. 121.
    Cruickshanks KJ, Ritter LL, Klein R, Moss SE. The association of microalbuminuria with diabetic retinopathy: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology. 1993;100:862–7.PubMedGoogle Scholar
  122. 122.
    Klein R, Moss SE, Klein BE. Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? Ophthalmology. 1993;100:1140–6.PubMedGoogle Scholar
  123. 123.
    Klein R. Diabetic retinopathy and nephropathy. In: Cortes P, Morgensen CE, eds. The diabetic kidney. Totowa, NJ: Humana Press; 2006.Google Scholar
  124. 124.
    Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed). 1988;296:156–60.Google Scholar
  125. 125.
    Jensen T, Deckert T. Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients. Horm Metab Res Suppl. 1992;26:68–70.PubMedGoogle Scholar
  126. 126.
    Gilbert RE, Tsalamandris C, Allen TJ, Colville D, Jerums G. Early nephropathy predicts vision-threatening retinal disease in patients with type I diabetes mellitus. J Am Soc Nephrol. 1998;9:85–9.PubMedGoogle Scholar
  127. 127.
    Lloyd CE, Klein R, Maser RE, Kuller LH, Becker DJ, Orchard TJ. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. J Diabetes Complications. 1995;9:140–8.PubMedGoogle Scholar
  128. 128.
    Lloyd CE, Orchard TJ. Diabetes complications: the renal-retinal link. An epidemiological perspective. Diabetes Care. 1995;18:1034–6.PubMedGoogle Scholar
  129. 129.
    Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis. 1998;31:947–53.PubMedGoogle Scholar
  130. 130.
    Kofoed-Enevoldsen A, Jensen T, Borch-Johnsen K, Deckert T. Incidence of retinopathy in type I (insulin-dependent) diabetes: association with clinical nephropathy. J Diabet Complications. 1987;1:96–9.PubMedGoogle Scholar
  131. 131.
    Nelson RG, Newman JM, Knowler WC, et al. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31:730–6.PubMedGoogle Scholar
  132. 132.
    Klein R, Zinman B, Gardiner R, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes. 2005;54:527–33.PubMedGoogle Scholar
  133. 133.
    Goldsmith JR, Landaw SA. Carbon monoxide and human health. Science. 1968;162:1352–9.PubMedGoogle Scholar
  134. 134.
    Hawkins RI. Smoking, platelets and thrombosis. Nature. 1972;236:450–2.PubMedGoogle Scholar
  135. 135.
    Klein R, Klein BE, Davis MD. Is cigarette smoking associated with diabetic retinopathy? Am J Epidemiol. 1983;118:228–38.PubMedGoogle Scholar
  136. 136.
    Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic retinopathy. Diabetes Care. 1991;14:119–26.PubMedGoogle Scholar
  137. 137.
    Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology. 1996;103:1438–42.PubMedGoogle Scholar
  138. 138.
    Klein R, Moss SE, Klein BE, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med. 1989;149:266–72.PubMedGoogle Scholar
  139. 139.
    Jakubowski JA, Vaillancourt R, Deykin D. Interaction of ethanol, prostacyclin, and aspirin in determining human platelet reactivity in vitro. Arteriosclerosis. 1988;8:436–41.PubMedGoogle Scholar
  140. 140.
    Kingsley LA, Dorman JS, Doft BH, et al. An epidemiologic approach to the study of retinopathy: the Pittsburgh Diabetic Morbidity and Retinopathy Studies. Diabetes Res Clin Pract. 1988;4:99–109.PubMedGoogle Scholar
  141. 141.
    Young RJ, McCulloch DK, Prescott RJ, Clarke BF. Alcohol: another risk factor for diabetic retinopa-thy? Br Med J (Clin Res Ed). 1984;288:1035–7.Google Scholar
  142. 142.
    Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 1998;116:297–303.PubMedGoogle Scholar
  143. 143.
    Moss SE, Klein R, Klein BE. The association of alcohol consumption with the incidence and progression of diabetic retinopathy. Ophthalmology. 1994;101:1962–8.PubMedGoogle Scholar
  144. 144.
    Valmadrid CT, Klein R, Moss SE, Klein BE, Cruickshanks KJ. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA. 1999;282:239–46.PubMedGoogle Scholar
  145. 145.
    Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363–5.PubMedGoogle Scholar
  146. 146.
    Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248:67–76.PubMedGoogle Scholar
  147. 147.
    Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothe-lial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96:1395–403.PubMedGoogle Scholar
  148. 148.
    Schram MT, Chaturvedi N, Schalkwijk C, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2003;26:2165–73.PubMedGoogle Scholar
  149. 149.
    Schalkwijk CG, Chaturvedi N, Twaafhoven H, van Hinsbergh VW, Stehouwer CD. Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest. 2002;32:500–6.PubMedGoogle Scholar
  150. 150.
    Powell ED, Field RA. Diabetic retinopathy and rheumatoid arthritis. Lancet. 1964;41:17–8.Google Scholar
  151. 151.
    Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257–9.PubMedGoogle Scholar
  152. 152.
    Funatsu H, Yamashita H, Ikeda T, Mimura T, Shimizu E, Hori S. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol. 2003;135:321–7.PubMedGoogle Scholar
  153. 153.
    Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295–301.PubMedGoogle Scholar
  154. 154.
    van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300–6.PubMedGoogle Scholar
  155. 155.
    Poston L, Taylor PD. Glaxo/MRS Young Investigator Prize. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci (Lond). 1995;88:245–55.Google Scholar
  156. 156.
    Taverna MJ, Sola A, Guyot-Argenton C, et al. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet Med. 2002;19:240–5.PubMedGoogle Scholar
  157. 157.
    Shibuki H, Katai N, Yodoi J, Uchida K, Yoshimura N. Lipid peroxidation and peroxynitrite in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2000;41:3607–14.PubMedGoogle Scholar
  158. 158.
    Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care. 2000;23:234–40.PubMedGoogle Scholar
  159. 159.
    Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci. 1999;40:689–96.PubMedGoogle Scholar
  160. 160.
    Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100:3131–9.PubMedGoogle Scholar
  161. 161.
    Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001;98:2604–9.PubMedGoogle Scholar
  162. 162.
    Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370–6.PubMedGoogle Scholar
  163. 163.
    Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care. 1997;20:1880–6.PubMedGoogle Scholar
  164. 164.
    Agardh CD, Agardh E, Andersson A, Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1994;54:637–41.PubMedGoogle Scholar
  165. 165.
    Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med. 2000;160:2984–90.PubMedGoogle Scholar
  166. 166.
    Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia. 2003;46:766–72.PubMedGoogle Scholar
  167. 167.
    Vaccaro O, Perna AF, Mancini FP, et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis. 2000;10:297–304.PubMedGoogle Scholar
  168. 168.
    Chiarelli F, Pomilio M, Mohn A, et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr. 2000;137:386–92.PubMedGoogle Scholar
  169. 169.
    Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1991;51:277–82.PubMedGoogle Scholar
  170. 170.
    Hultberg B, Agardh CD, Agardh E, Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study. Scand J Clin Lab Invest. 1997;57:595–600.PubMedGoogle Scholar
  171. 171.
    Gaede P, Vedel P, Parving HH, Pedersen O. Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. Nephrol Dial Transplant. 2001;16:2028–33.PubMedGoogle Scholar
  172. 172.
    Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci. 2000;41:2115–9.PubMedGoogle Scholar
  173. 173.
    Olson JA, Whitelaw CM, McHardy KC, Pearson DW, Forrester J V. Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia. 1997;40: 1166–71.PubMedGoogle Scholar
  174. 174.
    Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in strepto-zotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96:10836–41.PubMedGoogle Scholar
  175. 175.
    Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81–100.PubMedGoogle Scholar
  176. 176.
    Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today. 1993;14:111–5.PubMedGoogle Scholar
  177. 177.
    Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994;343:831–6.PubMedGoogle Scholar
  178. 178.
    Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci. 1992;667:324–31.PubMedGoogle Scholar
  179. 179.
    Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003;108:1917–23.PubMedGoogle Scholar
  180. 180.
    Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med. 2002;19:822–6.PubMedGoogle Scholar
  181. 181.
    Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: the World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia. 1985;28 Suppl:615–40.Google Scholar
  182. 182.
    LaPorte RE, Dorman JS, Tajima N, et al. Pittsburgh Insulin-Dependent Diabetes Mellitus Morbidity and Mortality Study: physical activity and diabetic complications. Pediatrics. 1986;78:1027–33.PubMedGoogle Scholar
  183. 183.
    van Leiden HA, Dekker JM, Moll AC, et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol. 2003;121:245–51.PubMedGoogle Scholar
  184. 184.
    Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1997;157:650–6.PubMedGoogle Scholar
  185. 185.
    Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care. 1990;13:741–7.PubMedGoogle Scholar
  186. 186.
    Kriska AM, LaPorte RE, Patrick SL, Kuller LH, Orchard TJ. The association of physical activity and diabetic complications in individuals with insulin-dependent diabetes mellitus: the Epidemiology of Diabetes Complications Study—VII. J Clin Epidemiol. 1991;44:1207–14.PubMedGoogle Scholar
  187. 187.
    Cruickshanks KJ, Moss SE, Klein R, Klein BE. Physical activity and proliferative retinopathy in people diagnosed with diabetes before age 30 yr. Diabetes Care. 1992;15:1267–72.PubMedGoogle Scholar
  188. 188.
    Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care. 1990;13:895–8.PubMedGoogle Scholar
  189. 189.
    Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999;22:1984–7.PubMedGoogle Scholar
  190. 190.
    Temple RC, Aldridge VA, Sampson MJ, Greenwood RH, Heyburn PJ, Glenn A. Impact of pregnancy on the progression of diabetic retinopathy in Type 1 diabetes. Diabet Med. 2001;18:573–7.PubMedGoogle Scholar
  191. 191.
    Lauszus F, Klebe JG, Bek T. Diabetic retinopathy in pregnancy during tight metabolic control. Acta Obstet Gynecol Scand. 2000;79:367–70.PubMedGoogle Scholar
  192. 192.
    Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34–40.PubMedGoogle Scholar
  193. 193.
    Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy: The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18:631–7.PubMedGoogle Scholar
  194. 194.
    Hemachandra A, Ellis D, Lloyd CE, Orchard TJ. The influence of pregnancy on IDDM complications. Diabetes Care. 1995;18:950–4.PubMedGoogle Scholar
  195. 195.
    Vaarasmaki M, Anttila M, Pirttiaho H, Hartikainen AL. Are recurrent pregnancies a risk in type 1 diabetes? Acta Obstet Gynecol Scand. 2002;81:1110–5.PubMedGoogle Scholar
  196. 196.
    Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061–70.PubMedGoogle Scholar
  197. 197.
    Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998–1003.PubMedGoogle Scholar
  198. 198.
    Klein R, Klein BE. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America, 2nd ed. Springfield, VA : National Institutes of Health. NIH Publication No. 95–1468; 1995:293–338.Google Scholar
  199. 199.
    Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.PubMedGoogle Scholar
  200. 200.
    Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol Scand. 2004;82:443–8.PubMedGoogle Scholar
  201. 201.
    Klein R, Klein BE, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142:539–49.PubMedGoogle Scholar
  202. 202.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864–71.PubMedGoogle Scholar
  203. 203.
    Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O'Brien D. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA. 1989;261:1155–60.PubMedGoogle Scholar
  204. 204.
    The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271–86.Google Scholar
  205. 205.
    Klein R, Klein BEK, Moss SE. Risk factors for retinopathy. In: Feman SS (ed). Ocular problems in diabetes mellitus. Boston: Blackwell Publishing; 1992:39.Google Scholar
  206. 206.
    Klein R. Diabetes mellitus: oculopathy. In: Degroot LJ, Jameson JL, eds. Endocrinology, 4th ed. Philadelphia, PA: WB Saunders; 1995:857–67.Google Scholar
  207. 207.
    Klein R, Klein BEK, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1–9.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Ronald Klein
    • 1
  1. 1.Department of Ophthalmology and Visual SciencesUniversity of Wisconsin School of Medicine and Public HealthMadison

Personalised recommendations